Immunity As Cornerstone Of Non-Alcoholic Fatty Liver Disease: The Contribution Of Oxidative Stress in The Disease Progression Part 2
Mar 02, 2023
5. Cov lus xaus
Qhov nyuaj ntawm NAFLD pathogenesis tsis tso cai rau tus kheej cov txheej txheem los ua incontrovertibly lub luag haujlwm rau kab mob kev loj hlob thiab kev loj hlob. Yog li ntawd, kev kho mob tshwj xeeb thiab muaj txiaj ntsig tseem tsis tau muaj, ua rau NAFLD lub nra hnyav thoob ntiaj teb. Txawm li cas los xij, ib qho kev txiav txim siab uas pab txhawb rau kev paub yog muab los ntawm kev tshawb fawb ntawm redox biology thiab kev tiv thaiv kab mob siab. Nws yog qhov paub zoo tias qhov redox tsis sib npaug yog koom nrog cov kab mob siab ntev thiab tag nrho cov theem NAFLD, qhia txog kev hloov pauv redox raws li qhov ua rau lub zog ntawm cov lus teb. Txawm li cas los xij, nws tseem tsis tau paub meej tias vim li cas qhov no tsuas yog tshwm sim rau ib feem ntawm cov neeg mob. Lub peev xwm kev koom tes ntawm kev tiv thaiv kab mob uas twb muaj lawm yuav tsum tau tshawb xyuas los piav qhia seb qhov redox imbalance puas cuam tshuam rau lub cev tiv thaiv kab mob.
Ntxiv mus, los ntawm kev tshawb fawb txog redox biology hauv lub cev tiv thaiv kab mob, cov ntawv ceeb toom tsis ntev los no tau nthuav tawm qhov tseem ceeb ntawm kev tiv thaiv kab mob hauv lub cev, tsim cov tswv yim tshiab xws li kev tiv thaiv kev tiv thaiv thiab qhia txog cov phiaj xwm kho mob tshiab. Yog li ntawd, kev nkag siab tob dua ntawm cov txheej txheem molecular hauv qab ntawm crosstalk ntawm redox biology thiab kev tiv thaiv kab mob yog xav tau los muab kev pabcuam tseem ceeb rau cov kev kho tshiab.
Nyem qhov no mus yuav cov khoom cistanche
For more information:1950477648nn@gmail.com
Tus sau kev koom tes:
Conceptualization, MD thiab AF; Resources, CL, thiab GS; Kev Sau Ntawv— Thawj Daim Ntawv Npaj, MD, MS, MR; Visualization, CL, thiab AF; Kev saib xyuas, RV thiab ADR; Project Administration, AF thiab MD Txhua tus kws sau ntawv tau nyeem thiab pom zoo rau cov ntawv luam tawm ntawm cov ntawv sau.
Nyiaj txiag:
Qhov kev tshawb fawb no tsis tau txais nyiaj txiag sab nraud.
Institutional Review Board Statement:
Tsis siv tau.
Cov Lus Qhia Txog Kev Pom Zoo:
Tsis siv tau.
Cov ntaub ntawv muaj nyob:
Tsis siv tau.
Kev lees paub:
Tus sawv cev ntawm cov qauv ntawm tes, txoj hauv kev molecular, thiab lwm yam hauv cov duab tau tsim los siv cov duab txhawb nqa thiab cov cim muaj uas muab los ntawm BioRender software.
Kev tsis sib haum xeeb ntawm kev txaus siab:
Cov kws sau ntawv tshaj tawm tsis muaj kev sib cav txog kev txaus siab.
Cov ntawv luv
AMPK Adenosine monophosphate-activated protein kinase
AP -1 Activator protein-1
APCs Antigen Presenting Cells
ASK 1 Apoptosis signal-regulating kinase 1
CAFs Cancer-associated fibroblasts
CCL-2 Chemokine (CC motif) ligand 2
CHOP C/EBP Homologous Protein
COX Cytochrome c oxidase
COX-2 Cyclooxygenase 2
CTLA CD14 ntxiv rau cytotoxic T-lymphocyte-associated protein
CXCL12 Chemokine CXC motif ligand 12
CYP Cytochrome P450
DAMPs Kev puas tsuaj cuam tshuam nrog cov qauv molecular
DC Dendritic cell
EGF Epidermal kev loj hlob yam
eIF2a RNA-dependent protein kinase-zoo li ER eukaryotic pib yam khoom -2 kinase\
ER Endoplasmic Reticulum
ETC Electron thauj saw
FAO Fatty acid oxidation
FFAs Dawb fatty acids
FGF Fibroblast kev loj hlob yam
FoxP3 Forkhead Box P3
HCC Hepatocellular Carcinoma
HFD noj cov rog rog
HGF Hepatocyte loj hlob yam
HIF-1 Hypoxia-inducible factor 1-alpha
HLA Human leukocyte antigen
HMGB1 siab zog pab pawg lub thawv 1 protein
HNE Dydroxinonenal
HO-1 Heme oxygenase-1
HSCs Hepatic stellate hlwb
ICI Immune checkpoint inhibitors
IFN-Interferon
IKK Inhibitor ntawm nuclear factor kappa-B kinase
IR Insulin Resistance
IRG1 Immune Responsive gene 1
JMJ Jumonji domain-muaj
JNK c-Jun-N-terminal kinase
KCs Kupffer hlwb
KEAP1 Kelch-zoo li ECH-koom nrog protein 1
LPSL lipopolysaccharides
MAA Malondialdehyde-acetaldehyde
MAFLD Metabolic (kev ua haujlwm tsis zoo) cuam tshuam rau lub siab rog
MAP3K Mitogen-activated protein kinase kinase
MAPK Mitogen-activated protein kinase.
MCSF Macrophage colony-stimulating factor
MDA Malondialdehyde
MDSCs Myeloid-derived suppressor hlwb
MMP Matrix metalloprotease
MPT Mitochondrial permeability hloov
MS Metabolic Syndrome
mTOR Mammalian hom phiaj ntawm rapamycin
NAFLD Non-alcoholic fatty siab kab mob
NASH Tsis-alcoholic steatohepatitis
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells
NK Natural Killer
NLRP NLR tsev neeg pyrin domain muaj
NLRS Nucleotide-binding oligomerization domain-zoo li receptors
NOX NADPH oxidase
Nrf2 Nuclear factor erythroid 2-related factor 2
OLRs Oligoadenylate synthase (OAS) zoo li receptors
OSEs Oxidation-specific epitopes
OXPHOS Oxidative phosphorylation
PAMPs Pathogen Associated Molecular Patterns
PDGF Platelet-Derived Growth Factor
PPARs Peroxisome proliferator-activated receptor
PD1 Programmed Cell Tuag 1
PRRs Pattern recognition receptors
PUFAs Polyunsaturated fatty acids
RAGEs Receptors rau qib siab glycation kawg khoom
ROS Reactive oxygen hom
SDH Succinate dehydrogenase
SNPs Tib Nucleotide Polymorphisms
SOD Superoxide dismutase
SPARC Secreted protein acidic nplua nuj nyob rau hauv cysteine
TAK 1 TGF- -activated kinase 1
TAMs Tumour-associated macrophages
TET Kaum kaum ib translocation
TGF- Transforming Growth Factor-
TI Tau Txais Kev Tiv Thaiv Kev Tiv Thaiv
TLRs Tus Xov Tooj Zoo li receptors
TNF- Tumor Necrosis Factor-
TRAIL Tumor necrosis yam ntsig txog apoptosis-inducing ligand (TRAIL)
Tregs Regulatory T cells
VEGF Vascular endothelial kev loj hlob yam
Cov ntaub ntawv
1. Bellentani, S. Kev kis mob ntawm cov kab mob uas tsis yog-alcoholic fatty siab kab mob. Lub siab thoob ntiaj teb. Tawm. J. Int. Assoc. Kawm Lub Siab 2017, 37 (Suppl. 1), 81–84.
2. Lindenmeyer, CC; McCullough, A. Lub Neej Keeb Kwm ntawm Kev Mob Ntshav Qab Zib Tsis Muaj Dej Haus—Ib qho Kev Pom Zoo. Clin. Lub siab Dis. 2018, 22, 11–21. [CrossRef] [PubMed]
3. Abenavoli, L.; Boccuto, L.; Federico, UA; Dallio, M.; ib. Logercio, C.; Di Renzo, L.; De Lorenzo, A. Kev Noj Qab Haus Huv, thiab Kab Mob Tsis Muaj Cawv Fatty Liver Disease: Txoj Kev Mediterranean. Int. J. Environ. Res. Public Heal. 2019, 16, 3011. [CrossRef] [PubMed]
4. Wijarnpreecha, K.; Aby, ES; Ahmed, UA; Kim, D. Kev Ntsuam Xyuas thiab Kev Tswj Xyuas Kev Tshaj Lij Tshaj Tawm ntawm Cov Kab Mob Ntshav Qab Zib Tsis Zoo. Clin. Mol. Hepatol. 2020, 14, 2, 168–178. [CrossRef]
5. Xamuyee, VT; Shulman, GI Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic thiab Hepatic Diseases. Cell Metab. 2018, 27, 22–41. [CrossRef]
6. Federico, A.; Dallio, M.; ib. Masarone, M.; Persico, M.; Loguercio, C. Cov kab mob ntawm cov kab mob uas tsis yog-alcoholic fatty siab kab mob thiab nws cov kev sib txuas nrog cov kab mob plawv: Lub luag hauj lwm ntawm endothelial dysfunction. Eur. Rev. Med. Pharmacol. Sci. 2016, 20, 4731–4741.
7. Saklayen, MG Lub Ntiaj Teb Kab Mob Sib Kis ntawm Metabolic Syndrome. Curr. Hypertens. Rep. 2018, 20, 1–8. [CrossRef]
8. Masarone, M.; Federico, UA; Abenavoli, L. Logercio, C.; Persico, M. Non Alcoholic Fatty Liver: Epidemiology and Natural History. Rev. Tsis ntev los no Clin. 2015, 9, 126–133. [CrossRef]
9. Younossi, ZM; Blissett, D.; Blissett, R.; Henry, L.; Stepanova, M. Younossi, Y.; Racila, UA; Hunt, S.; Beckerman, R. Kev lag luam thiab kev kho mob lub nra ntawm cov kab mob uas tsis yog-coholic fatty siab hauv Tebchaws Meskas thiab Europe. Hepatology 2016, 64, 1577–1586. [CrossRef]
10. Sherlock, S. Sherlock's Diseases of the Liver and Biliary System, 13th ed.; Dooley, JS, Garcia-Tsao, G., Pinzani, M., Eds.; John Wiley & Sons Ltd: Hoboken, NJ, USA, 2018; Phau 28, p. 540–560. [CrossRef]
11. Dallio, M.; Masarone, M.; Errico, S.; ib. Gravina, UA; Nicolucci, C.; Di Sarno, R.; Gionti, L.; Tuccilo, C.; Persico, M.; Stiuso, P.; ua al. Lub luag haujlwm ntawm bisphenol A raws li ib puag ncig ib puag ncig hauv kev txhawb nqa cov kab mob tsis muaj dej cawv fatty siab: Hauv vitro thiab kev tshawb fawb soj ntsuam. Khoom noj khoom haus. Pharmacol. Ther. Xyoo 2018, 47, 826–837. [CrossRef]
12. Eslam, M.; Sanyal, AJ; George, J. International Consensus Panel. MAFLD: Ib Daim Ntawv Pom Zoo-Driven Proposed Nomenclature rau Metabolic Associated Fatty Liver Disease. Gastroenterology 2020, 158, 1999–2014.e1. [CrossRef] [PubMed]
13. Pierantonelli, I.; Svegliati-Baroni, G. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression from NAFLD to NASH. Hloov pauv xyoo 2019, 103, e1–e13. [CrossRef] [PubMed]
14. Masarone, M.; Rosato, V.; Dallio, M.; ib. Gravina, UA; Aglitti, UA; Logercio, C.; Federico, UA; Persico, M. Lub luag haujlwm ntawm Oxidative Stress hauv Pathphysiology ntawm Nonalcoholic Fatty Liver Disease. Oxidative Med. Cell. Longev. Xyoo 2018, 1-14. [CrossRef] [PubMed]
15. Patterson, RE; Kalavalapalli, S.; Williams, WM; Nautiyal, M.; Mathew, JT; Martinez, J.; Reinhard, MK; McDougall, DJ; Rocca, JR; Yog, RA; ua al. Lipotoxicity hauv steatohepatitis tshwm sim txawm tias muaj kev nce hauv tricarboxylic acid voj voog kev ua haujlwm. Am. J. Physiol. Metab. 2016, 310, E484–E494. [CrossRef] [PubMed]
16. Sutti, S.; Albano, E. Adaptive immunity: Ib tus neeg ua si tshiab hauv kev nce qib ntawm NAFLD. Nat. Rev. Gastroenterol. Hepatol. Xyoo 2019, 17, 81–92. [CrossRef] [PubMed]
17. Cai, J.; Zhang, X.-J.; Li, H. Lub luag haujlwm ntawm Innate Immune Signaling in Non-Alcoholic Fatty Liver Disease. Trends Endocrinol. Metab. Xyoo 2018, 29, 712–722. [CrossRef]
18. Jadeja, RN; Devkar, R.; Nammi, S. Oxidative Stress in Liver Disease: Pathogenesis, Kev Tiv Thaiv, thiab Kev Kho Mob. Oxidative Med. Cell. Longev. 2017, 2017, 1–2. [CrossRef]
19. Buzzetti, E.; Pinzani, M.; Tsochatzis, E. The multiple- hit pathogenesis of the non-alcoholic fatty liver disease (NAFLD). Metab. Clin. Exp. 2016, 65, 1038–1048. [CrossRef]
20. Forrester, SJ; Kikuchi, DS; Hernandes, NWS; Xu, Q. Griendling, KK Reactive Oxygen Hom hauv Metabolic thiab Inflammatory Signaling. Circ. Res. 2018, 122, 877–902. [CrossRef]
21. Serviddio, G.; Bellanti, F.; Vendemiale, G. Dawb radical biology rau tshuaj: Kawm los ntawm nonalcoholic fatty siab kab mob. Dawb. Radic. Biol. Med. Xyoo 2013, 65, 952–968. [CrossRef]
22. Bigarella, CL; Liang, R.; Ghaffari, S. Stem cells thiab qhov cuam tshuam ntawm ROS signaling. Kev txhim kho 2014, 141, 4206–4218. [CrossRef] [PubMed]
23. Muas, JM; Sanchez-Jimenez, F. Antioxidant enzymes thiab lawv qhov cuam tshuam hauv cov txheej txheem pathophysiologic. Frontiers nyob rau hauv bioscience. J. Virtual Libr. Xyoo 1999, 4, D339–D345. [CrossRef]
24. Zhou, L.; Wang, X.; Cueto, R.; Efi, C.; Zhang, YJ; Tan, H.; Qin, X.; Ji, Y.; Yang, X.; Wang, H. Biochemical hauv paus thiab metabolic interplay ntawm kev cai redox. Redox Biol. 2019, 26, 101284. [CrossRef] [PubMed]
25. Takaki, A.; Cai, D.; Yamamoto, K. Ntau Ntaus, suav nrog Oxidative Stress, raws li Pathogenesis thiab Kev Kho Mob Lub Hom Phiaj hauv Non-Alcoholic Steatohepatitis (NASH). Int. J. Mol. Sci. 2013, 14, 20704–20728. [CrossRef] [PubMed]
26. Bellanti, F.; Villani, R.; Faciorusso, A.; Vendemiale, G.; Serviddio, G. Lipid oxidation khoom nyob rau hauv lub pathogenesis ntawm non-alcoholic steatohepatitis. Dawb. Radic. Biol. Med. 2017, 111, 173–185. [CrossRef]
27. Bellanti, F.; Villani, R.; Tamborra, R.; Blonda, M.; Iannelli, G.; Di Bello, G.; Faciorusso, A.; Poli, G.; Iuliano, L.; Avolio, C.; ua al. Kev sib koom ua ke ntawm fatty acids thiab oxysterols impairs mitochondrial muaj nuj nqi thiab txwv lub siab hloov thaum lub sij hawm NAFLD kev loj hlob. Redox Biol. Xyoo 2017, 15, 86-96. [CrossRef]
28. Sangineto, M.; Villani, R.; Cavalone, F.; Romano, AD; Loos, D.; Serviddio, G. Lipid Metabolism hauv Kev Loj Hlob thiab Kev Loj Hlob ntawm Hepatocellular Carcinoma. Cancers 2020, 12, 1419. [CrossRef]
29. Serviddio, G.; Bellanti, F.; Vendemiale, G.; Altomare, E. Mitochondrial dysfunction nyob rau hauv nonalcoholic steatohepatitis. Kws txawj Rev. Gastroenterol. Hepatol. 2011, 5, 233–244. [CrossRef]
30. Serviddio, G.; Giudetti, AM; Bellanti, F.; Ua ntej, P.; Rollo, T.; Tamborra, R.; Siculella, L.; Vendemiale, G.; Altomare, E.; Gnoni, GV Oxidation ntawm Hepatic Carnitine Palmitoyl Transferase-I (CPT-I) Impairs Fatty Acid Beta-Oxidation nyob rau hauv nas pub noj MethionineCholine tsis txaus noj. PLoS IB 2011, 6, e24084. [CrossRef]
31. Friedman, SL; Neuschwander-Tetri, BA; Rinella, M.; ib. Sanyal, AJ Mechanisms ntawm NAFLD kev txhim kho thiab cov tswv yim kho mob. Nat. Med. Xyoo 2018, 24, 908–922. [CrossRef]
32. Chen, Z.; yus, Y.; Cai, J.; Li, H. Emerging Molecular Targets rau kev kho mob ntawm Nonalcoholic Fatty Liver Disease. Trends Endocrinol. Metab. Xyoo 2019, 30, 903–914. [CrossRef] [PubMed]
33. Schieber, M.; Chandel, NS ROS Function hauv Redox Signaling thiab Oxidative Stress. Curr. Biol. Xyoo 2014, 24, R453–R462. [CrossRef] [PubMed]
34. Mansouri, A.; Gattolliat, C.-H.; Asselah, T. Mitochondrial Dysfunction thiab Signaling in Chronic Liver Diseases. Gastroenterology 2018, 155, 629–647. [CrossRef] [PubMed]
35. Simões, IC; Fontes, A.; Pinton, P.; Zischka, H.; Wieckowski, MR Mitochondria nyob rau hauv uas tsis yog-alcoholic fatty siab kab mob. Int. J. Biochem. Cell Bio. Xyoo 2018, 95, 93–99. [CrossRef]
36. García-Ruiz, I.; Rodríguez-Juan, C.; Díaz-Sanjuan, T.; Del Hoyo, P.; Colina, F.; Muñoz-Yagüe, T.; Solís-Herruzo, JA Uric acid, thiab anti-TNF antibody txhim kho mitochondrial dysfunction hauv ob / ob nas. Hepatology 2006, 44, 581–591. [CrossRef]
37. Garcia-Ruiz, I.; Rodriguez-Juan, C.; Diaz-Sanjuan, T.; Martinez, MA; Munoz-Yague, T.; Solis-Herruzo, JA Cov teebmeem ntawm rosiglitazone ntawm daim siab histology thiab mitochondrial muaj nuj nqi hauv ob / ob nas. Hepatology 2007, 46, 414–423. [CrossRef]
38. Li, Z.; Yaj, S.; Lin, H.; Huang, J.; Watkins, PA; Moser, AB; DeSimone, C.; Nkauj, X.; Diehl, AM Probiotics thiab cov tshuaj tiv thaiv kab mob rau TNF inhibit inflammatory kev ua haujlwm thiab txhim kho cov kab mob uas tsis yog-coholic fatty siab. Hepatology 2003, 37, 343–350. [CrossRef]
38. Li, Z.; Yaj, S.; Lin, H.; Huang, J.; Watkins, PA; Moser, AB; DeSimone, C.; Nkauj, X.; Diehl, AM Probiotics thiab cov tshuaj tiv thaiv kab mob rau TNF inhibit inflammatory kev ua haujlwm thiab txhim kho cov kab mob uas tsis yog-coholic fatty siab. Hepatology 2003, 37, 343–350. [CrossRef]
40. Romestaing, C.; Piquet, MA; Letexier, D.; Rau, B.; Mourier, A.; Servais, S.; Belouze, M.; Rouleau, V.; Dautresme, M.; Ollivier, ib.; ua al. Mitochondrial adaptations rau steatohepatitis induced los ntawm methionine- thiab choline-tsis noj zaub mov. American Journal of Physiology. Endocrinol. Metab. 2008, 294, E110–E119
41. Koliaki, C.; Szendroedi, J.; Kaul, K.; Jelenik, T.; Nowotny, P.; Jankowiak, F.; Herder, C.; Carstensen-Kirberg, M.; Krausch, M.; ib. Knoefel, WT; ua al. Kev hloov kho ntawm Hepatic Mitochondrial Function nyob rau hauv tib neeg nrog Tsis-Alcoholic Fatty Liver yog ploj hauv Steatohepatitis. Cell Metab. 2015, 21, 739–746. [CrossRef]
42. Bugianesi, E.; Gastaldelli, UA; Vanni, E.; Gambino, R.; Cassader, M.; Baldi, S.; Ponti, V.; Pagano, G.; Ferranni, E.; Rizzetto, M. Insulin tsis kam nyob rau hauv cov neeg mob uas tsis yog mob ntshav qab zib mellitus nrog cov kab mob uas tsis yog-alcoholic fatty siab: Cov chaw thiab cov txheej txheem. Diabetologia 2005, 48, 634–642. [CrossRef] [PubMed]
43. Chalasani, N.; Gorski, JC; Asghar, MS; Asghar, UA; Tus Thawj Coj, B.; Hall, SD; Crabb, DW Hepatic cytochrome P450 2E1 kev ua haujlwm hauv cov neeg mob uas tsis muaj ntshav qab zib uas tsis muaj dej cawv steatohepatitis. Hepatology 2003, 37, 544–550. [CrossRef] [PubMed]
44. Dasarathy, S.; Kasumov, T.; Edmison, JM; Gruca, LL. Bennett, C.; ib. Duenas, C.; Marczewski, S.; McCullough, AJ; Hanson, RWM; Kalhan, S. Glycine thiab urea kinetics hauv nonalcoholic s
45. Dasarathy, S.; Yaj, Y.; McCullough, AJ; Marczewski, S.; Bennett, C.; ib. Kalhan, SC Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, thiab fasting bile acids in nonalcoholic steatohepatitis. Eur. J. Gastroenterol. Hepatol. 2011, 23, 382–388. [CrossRef]
46. Hodson, L.; McQuaid, SE; Humphreys, SM; Milne, R.; ib. Fielding, IB; Frayn, KN; Karpe, F. Kev noj zaub mov ntau dua cov rog oxidation hauv rog piv nrog cov txiv neej lean: Ib qho kev hloov kho los tiv thaiv daim siab rog? Am. J. Physiol. Metab. 2010, 299, E584–E592. [CrossRef]
47. Miele, L.; Grieco, UA; Armuzzi, ib.; Candelli, M. Forgione, A.; Gasbarrini, UA; Gasbarrini, G. Hepatic mitochondrial beta-oxidation nyob rau hauv cov neeg mob uas tsis yog-coholic steatohepatitis soj ntsuam los ntawm 13C-octanoate ua pa kuaj. Am. J. Gastroenterol. 2003, 98, 2335–2336. [CrossRef]
48. Sanyal, AJ; Campbell–Sargent, C.; Mirshahi, F.; Rizzo, WB; Contos, MJ; Sterling, RK; Luketic, VA; Shiffman, ML; Clore, JN Nonalcoholic steatohepatitis: Koom Haum ntawm insulin tsis kam thiab mitochondrial abnormalities. Gastroenterology 2001, 120, 1183–1192. [CrossRef]
49. Schneider, ARJ; Kraut, C.; Lindenthal, IB; Braden, IB; Caspary, WF; Stein, J. Tag nrho lub cev metabolism ntawm 13C-octanoic acid yog khaws cia rau hauv cov neeg mob uas tsis yog-alcoholic steatohepatitis, tab sis txawv ntawm cov poj niam thiab cov txiv neej. Eur. J. Gastroenterol. Hepatol. 2005, 17, 1181–1184. [CrossRef]
50. Mawatari, H.; Inamori, M.; Fujita, K.; Yoneda, M.; Ib, H.; Endo, H.; Hosono, K.; Nozaki, Y.; Yoneda, K.; Akiyam, T.; ua al. Kev ntsuas ua pa tsis tu ncua ntawm 13C-octanoate ua pa rau cov neeg mob uas tsis muaj cawv steatohepatitis siv BreathID system. Hepatogastroenterology 2009, 56, 1436–1438.
51. Pérez-Carreras, M.; Del Hoyo, P.; Martin, MA; Rubio, JC; Martin, A.; Castellano, G. Colina, F.; Arenas, J.; ib. Solis-Herruzo, JA Defective hepatic mitochondrial respiratory saw nyob rau hauv cov neeg mob uas tsis yog-coholic steatohepatitis. Hepatology 2003, 38, 999–1007. [CrossRef]
52. Petersen, KF; Befroy, DE; Dufour, S.; Rothman, DL; Shulman, GI Kev Ntsuas ntawm Hepatic Mitochondrial Oxidation thiab Pyruvate Cycling hauv NAFLD los ntawm 13 C Sib Nqus Resonance Spectroscopy. Cell Metab. 2016, 24, 167–171. [CrossRef] [PubMed]
53. Kakimoto, PA; Chaw, B.; Caldeira da Silva, CC; Donato Junior, J.; Kowaltowski, AJ Resilient hepatic mitochondrial muaj nuj nqi thiab tsis muaj iNOS dependence nyob rau hauv kev noj haus-induced insulin kuj. PLoS IB 2019, 14, e0211733. [CrossRef] [PubMed]
54. George, J.; Liddle, C. Nonalcoholic fatty siab kab mob: Pathogenesis thiab muaj peev xwm rau nuclear receptors raws li kev kho lub hom phiaj. Mol. Pharm. 2008, 5, 49–59. [CrossRef] [PubMed]
55. Yamaguchi, K.; Yaj, L.; McCall, S.; Huang, J.; Yus, XX; Pandey, SK; Bhanot, S.; Monia, BP; Li, Y.-X.; Diehl, AM Inhibiting triglyceride synthesis txhim kho hepatic steatosis tab sis exacerbates daim siab puas thiab fibrosis nyob rau hauv cov nas rog rog nrog nonalcoholic steatohepatitis. Hepatology 2007, 45, 1366–1374. [CrossRef] [PubMed]
56. Satapati, S.; Sunny, NE; Kucejova, IB; Fu, X.; Nws, TT; Méndez-Lucas, A.; Shelton, JM; Perales, JC; Browning, JD; Burgess, SC Elevated TCA lub voj voog ua haujlwm nyob rau hauv pathology ntawm kev noj zaub mov-vim cov tshuaj insulin tsis kam thiab lub siab rog. J. Lipid Res. 2012, 53, 1080–1092. [CrossRef] [PubMed]
57. Cocco, T.; Di Paola, M.; Papa, P.; Lorusso, M. Arachidonic acid kev sib cuam tshuam nrog cov mitochondrial electron thauj saw txhawb nqa reactive oxygen hom tiam. Dawb. Radic. Biol. Med. Xyoo 1999, 27, 51–59. [CrossRef]
58. Loskovich, MV; Grivennikova, VG; Cecchini, G.; Vinogradov, AD Inhibitory effect of palmitate on the mitochondrial NADH: ubiquinone oxidoreductase (complex I) as related to active-de-active enzyme transition. Biochem. J. 2005, 387, 677–683. [CrossRef]
59. Schönfeld, P.; Reiser, G. Rotenone-zoo li Action ntawm Branched-chain Phytanic Acid Induces Oxidative Stress hauv Mitochondria. J. Biol. Chem. 2006, 281, 7136–7142. [CrossRef]
60. Schönfeld, P.; Wojtczak, L. Fatty acids txo qis mitochondrial tiam ntawm cov pa oxygen reactive ntawm kev thauj mus los ntawm electron rov qab tab sis nce nws ntawm kev thauj mus los. Biochim. Biophys. Acta Bioenerg. 2007, 1767, 1032–1040. [CrossRef]
61. Gille, L.; Nohl, H. The Ubiquinol/bc1 Redox Couple Regulates Mitochondrial Oxygen Radical Formation. Arch. Biochem. Biophys. 2001, 388, 34–38. [CrossRef]
62. Schönfeld, P.; Struy, H. Refsum tus kab mob diagnostic marker phytanic acid hloov lub cev lub cev ntawm daim nyias nyias proteins ntawm daim siab mitochondria. PEB Lett. 1999, 457, 179–183, ib. [CrossRef]
63. Serviddio, G.; Blonda, M.; Bellanti, F.; Villani, R.; Iuliano, L.; Vendemiale, G. Oxysterols thiab redox signaling nyob rau hauv pathogenesis ntawm tus kab mob tsis-alcoholic fatty siab kab mob. Dawb. Radic. Res. Xyoo 2013, 47, 881–893. [CrossRef] [PubMed]
64. Aws, M.; Plaub, G.; Michel, F.; Bonafos, IB; Ramos, J.; Cristol, JP; Carbonneau, M.-A.; Coudray, C.; Feillet-Coudray, C. Dietary fatty acids modulate daim siab mitochondrial cardiolipin cov ntsiab lus thiab nws cov fatty acid muaj pes tsawg leeg nyob rau hauv cov nas uas muaj cov kab mob nonalcoholic fatty siab. J. Bioenerg. Biomembr. 2012, 44, 439–452. [CrossRef] [PubMed]
65. Flamment, M.; Arvier, M.; ib. Gallois, Y.; Simard, G.; Malthièry, Y.; Ritz, P. Ducluzeau-Fieloux, P.-H. Lub siab rog thiab insulin tsis kam nyob rau hauv cov rog Zucker nas: Tsis muaj lub luag haujlwm rau kev ua haujlwm mitochondrial. Biochimie 2008, 90, 1407–1413. [CrossRef] [PubMed]
66. Flamment, M.; Rieusset, J.; Vidal, H.; Simard, G.; Malthièry, Y.; Lossis, B.; Ducluzeau, P.-H. Kev tswj hwm ntawm hepatic mitochondrial metabolism hauv teb rau kev noj zaub mov muaj rog: Kev tshawb fawb ntev hauv cov nas. J. Physiol. Biochem. 2012, 68, 335–344. [CrossRef] [PubMed]
67. Nadal-Casellas, A.; Amengual-Cladera, E.; Proenza, AM; Lladó, ib.; Gianotti, M. Long-term High-fat-food noj Impairs Mitochondrial Biogenesis nyob rau hauv daim siab ntawm txiv neej thiab poj niam nas. Cell. Physiol. Biochem. 2010, 26, 291–302. [CrossRef] [PubMed]
68. Vial, G.; Dubouchaud, H.; Couturier, K.; Cottet-Rousselle, C.; Taus, N.; Athias, A.; Galinier, UA; Castilla, L. Leverve, XM Cov teebmeem ntawm kev noj zaub mov muaj roj ntau ntawm lub zog metabolism thiab ROS ntau lawm hauv daim siab nas. J. Hepatol. 2011, 54, 348–356. [CrossRef]
69. Wardlaw, GM; Kaplan, ML Oxygen Consumption thiab Oxidative Peev Xwm ntawm Hepatocytes los ntawm Cov Txiv Neej Hluas Obese thiab Nonobese Zucker nas. Exp. Biol. Med. 1986, 183, 199–206. [CrossRef]
70. Poussin, C.; Iberson, M.; Hall, D.; Ding, J.; Tso, J.; Abel, ED; Thorens, B. Oxidative Phosphorylation Flexibility nyob rau hauv daim siab ntawm nas Resistant rau High-Fat Diet-Induced Hepatic Steatosis. Ntshav Qab Zib 2011, 60, 2216–2224. [CrossRef]
71. Satapati, S.; Kucejova, IB; Duarte, JA; Fletcher, JA; Reynolds, L.; Sunny, NE; Nws, T.; Nair, LA; Livingston, KA; Fu, X.; ua al. Mitochondrial metabolism mediates oxidative kev nyuaj siab thiab o ntawm lub siab rog. J. Clin. Tshawb xyuas. 2015, 125, 4447–4462. [CrossRef]
72. Valdecantos, MP; Pérez-Matute, P. González-Muniesa, P. Prieto-Hontoria, PL; Moreno-Aliaga, MJ; Martínez, JA Lipoic acid tswj hwm tiv thaiv tsis muaj cawv steatosis txuas rau kev noj zaub mov kom ntev ntev los ntawm kev hloov kho mitochondrial muaj nuj nqi. J. Nutr. Biochem. 2012, 23, 1676–1684. [CrossRef] [PubMed]
73. Carmiel-Haggai, M.; Cederbaum, AI; Nieto, N. Kev noj zaub mov muaj roj ntau ua rau muaj kev nce qib ntawm cov kab mob uas tsis yog-alcoholic fatty siab kab mob hauv cov nas rog rog. FASEB J. 2004, 19, 136–138. [CrossRef]
74. Cortez-Pinto, H.; Chaw, J.; Chacko, VP; Arnold, C.; Rashid, UA; Diehl, AM Alterations nyob rau hauv daim siab ATP homeostasis nyob rau hauv tib neeg nonalcoholic steatohepatitis: Ib tug pilot txoj kev tshawb no. JAMA 1999, 282, 1659–1664. [CrossRef] [PubMed]
75. Jiang, Y.; Zhou, M.; Ib, W. Kev nce siab apoptosis hauv kev noj zaub mov muaj roj ntau vim NASH hauv cov nas tuaj yeem cuam tshuam nrog kev txo qis ntawm cov tshuaj lom neeg lub siab. J. Mol. Med. 2011, 89, 1207–1217. [CrossRef] [PubMed]
76. Kev, C.; Duluc, L.; Chalopin, M.; Simard, G.; Ducluzeau, P.-H.; Herrera, MD; De Sotomayor, MA; Andriantsitohaina, R. Propionyl-L-carnitine Kho Metabolic thiab Cardiovascular Alterations nyob rau hauv noj cov nas rog rog thiab txhim kho daim siab ua pa Chain Activity. PLoS ONE 2012, 7, e34268. [CrossRef] [PubMed]
77. Fuchs, CD; Klaudel, T.; Scharnagl, H.; Stojakovic, T. Trauner, M. FXR tswj CHOP qhia hauv steatohepatitis. PEB Lett. 2017, 591, 3360–3368. [CrossRef] [PubMed]
78. Nkauj, B.; Scheuner, D.; Ron, D.; Pennathur, S.; Kaufman, RJ Chop deletion txo oxidative kev nyuaj siab, txhim kho cell muaj nuj nqi, thiab txhawb cell ciaj sia nyob rau hauv ntau yam nas qauv ntawm ntshav qab zib. J. Clin. Tshawb xyuas. 2008, 118, 3378–3389. [CrossRef]
79. Ashraf, NU; Sheikh, TA Endoplasmic reticulum stress thiab Oxidative stress in the pathogenesis of Non-alcoholic fatty liver disease. Dawb. Radic. Res. 2015, 49, 1405–1418. [CrossRef]
80. Cao, SS; Kaufman, RJ Endoplasmic Reticulum Stress thiab Oxidative Stress hauv Cell Fate Decision thiab Tib Neeg Kab Mob. Antioxidant. Redox teeb liab. 2014, 21, 396–413. [CrossRef]
81. Malhotra, JD; Kaufman, RJ Endoplasmic Reticulum Stress thiab Oxidative Stress: Ib Lub voj voog Vicious lossis ob-Edged ntaj? Antioxidant. Redox teeb liab. 2007, 9, 2277–2294. [CrossRef]
82. Cullinan, SB; Diehl, JA PERK-dependent Activation of Nrf2 Pab txhawb rau Redox Homeostasis thiab Cell Survival tom qab Endoplasmic Reticulum Stress. J. Biol. Chem. 2004, 279, 20108–20117. [CrossRef] [PubMed]
83. Yaj, Y.; Bazhin, AV; Werner, J.; Karakhanova, S. Reactive Oxygen Hom nyob rau hauv lub cev tiv thaiv kab mob. Int. Rev. Immunol. 2013, 32, 249–270. [CrossRef] [PubMed]
84. Schreck, R.; Rieb, P.; Baeuerle, PA Reactive oxygen intermediates raws li cov tub txib siv dav hauv kev ua kom NF-kappa B transcription factor thiab HIV-1. EMBO J. 1991, 10, 2247–2258. [CrossRef] [PubMed]
85. Li, S.; Hong, M.; Tan, H.-Y.; Wang, N.; Feng, Y. Kev nkag siab rau lub luag haujlwm thiab kev cuam tshuam ntawm Oxidative Stress thiab Inflammation hauv Kab Mob Siab. Oxidative Med. Cell. Longev. 2016, 2016, 1–21. [CrossRef]
86. Mittal, M.; Siddiqui, MR; Tran, K.; Reddy, SP; Malik, AB Reactive Oxygen Species in Inflammation and Tissue Injury. Antioxidant. Redox teeb liab. 2014, 20, 1126–1167. [CrossRef]
87. Ib., C.; Papa, S.; Pham, CG; Zazzeroni, F.; Franzoso, G. The NF-kappaB-mediated control of ROS and JNK signaling. Hisol. Histopathol. 2006, 21, 69–80.
88. Zhu, LH; Wang, UA; Luo, P.; Wang, X.; Jiang, D.-S.; Deng, W.; Zhang, X.; Vang, T.; Liu, Y.; Gao, L.; ua al. Mindin / Spondin 2 inhibits hepatic steatosis, insulin tsis kam, thiab rog dhau los ntawm kev cuam tshuam nrog peroxisome proliferator-activated receptor hauv nas. J. Hepatol. 2014, 60, 1046–1054. [CrossRef]
89. Wang, X.-A.; Deng, S.; Jiang, D.; Zhang, R. Zhang, S.; Zhou, J.; Yaj, L.; Vang, T.; Hong, S.; Guo, S.; ua al. CARD3 Deficiency Exacerbates Diet-Induced Obesity, Hepatosteatosis, thiab Insulin Resistance nyob rau txiv neej nas. Endocrinology 2013, 154, 685–697. [CrossRef]
90. Tig, J.; Han, CJ; Zhang, ZJ; Nws, WZ; Zhao, GJ; Cheng, X.; Zhang, L. Deng, KQ; Liu, Y.; Ntxuam, HF; ua al. Hepatic Interferon Regulatory Factor 6 Alleviates Liver Steatosis thiab Metabolic Disorder los ntawm Transcriptionally Suppressing Peroxisome Proliferator-Activated Receptor gamma hauv nas. Hepatology 2019, 69, 2471–2488.
91. Wang, P.-X.; Zhang, R. Huang, L.; Zhou, L.-H.; Jiang, D.-S.; Chen, H.-Z.; Zhang, YJ; Tian, S.; Zhang, X.-F.; Liu, D.; ua al. Interferon regulatory factor 9 yog tus kws kho mob tseem ceeb ntawm hepatic ischemia / reperfusion raug mob. J. Hepatol. 2015, 62, 111–120. [CrossRef]
92. Hu, J.; Zhu, X.-H.; Zhang, X.-J.; Wang, P.-X.; Zhang, R. Zhang, P. Zhao, G.-N.; Gao, L.; Tian, S.; Li, H. Targeting TRAF3 signaling tiv thaiv hepatic ischemia/reperfusions raug mob. J. Hepatol. 2016, 64, 146–159. [CrossRef] [PubMed]
93. Chen, L.; Huang, J.; Ji, YX; Mei, F.; Wang, PX; Deng, KQ; Jiang, X.; Ma, G.; Li, H. Tripartite Motif 8 Pab txhawb rau Pathological Cardiac Hypertrophy Los ntawm Kev Txhim Kho Kev Txhim Kho Kev Loj Hlob Factor beta-Activated Kinase 1-Txoj Kev Qhia Teeb Meem. Ntshav siab 2017, 69, 249–258. [CrossRef] [PubMed]
94. Zhao, G.-N.; Zhang, P. Koob, J.; Zhang, X.-J.; Wang, P.-X.; Yim, M.; Jiang, Z.; Shen, L.-J.; Ji, Y.-X.; Tong, J.; ua al. Tmbim1 yog tus tswj hwm lub cev ntau lub cev uas tiv thaiv cov kab mob tsis muaj dej cawv fatty siab hauv cov nas thiab liab los ntawm kev tsom mus rau lysosomal degradation ntawm Tlr4. Nat. Med. Xyoo 2017, 23, 742–752. [CrossRef] [PubMed]
95. Yan, Z.; Huang, Y.; Wang, X.; Wang, H.; Rau, F.; Tian, R.; Cheng, X.; Cai, J.; Zhang, YJ; Zhu, X.; ua al. Integrated Omics nthuav tawm Tollip ua tus tswj hwm thiab kho lub hom phiaj rau Hepatic Ischemia-Reperfusion Injury hauv nas. Hepatology 2019, 70, 1750–1769. [CrossRef] [PubMed]
96. Cai, J.; Xu, M.; Zhang, X.; Li, H. Innate Immune Signaling in Nonalcoholic Fatty Liver Disease and Cardiovascular Disease. Annu. Rev. Pathol. Mech. Dis. 2019, 14, 153–184. [CrossRef]
97. Federico, A.; Caprio, GG; Ormando, VM; Loguercio, C. Gut Microbiota thiab Kab Mob plab, Kab Mob Siab thiab Pancreas: Los ntawm Physiology mus rau Pathology. Minerva Gastroenterol. Paub meej. 2017, 63, 385–398.
98. Luedde, T.; Schwabe, RF NF-kappaB nyob rau hauv lub siab-txuas kev raug mob, fibrosis thiab hepatocellular carcinoma. Ntuj tshuaj xyuas. Gastroenterol. Hepatol. 2011, 8, 108–118.
99. Li, L.; Gao, J.; Li, J. Emerging lub luag hauj lwm ntawm HMGB 1 nyob rau hauv cov kab mob fibrotic. J. Cell. Mol. Med. 2014, 18, 2331–2339. [CrossRef]
100. Al-Khafaji, AB; Taum, S.; Yazdani, HO; Miller, D.; Huang, H.; Tsung, A. Superoxide induces Neutrophil Extracellular Trap Formation in a TLR-4 thiab NOX-Dependent Mechanism. Mol. Med. 2015, 22, 621–631. [CrossRef]
101. Garcia-Martinez, I.; Santoro, N.; Chen, Y.; Hoque, R.; Ouyang, X.; Caprio, S.; Shlomchik, MJ; Coffman, RL; Candia, UA; Mehal, WZ Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis los ntawm kev ua kom TLR9. J. Clin. Tshawb xyuas. Xyoo 2016, 126, 859–864. [CrossRef]
102. Gan, LT; Van Rooyen, DM; Koina, ME; McCuskey, RS; Teoh, NC; Farrell, GC Hepatocyte free cholesterol lipotoxicity tshwm sim los ntawm JNK1-kev kho mob mitochondrial raug mob thiab yog HMGB1 thiab TLR4- nyob ntawm. J. Hepatol. 2014, 61, 1376–1384. [CrossRef] [PubMed]
103. Begriche, K.; Igoudjil, A.; Pessayre, D.; Fromenty, B. Mitochondrial dysfunction hauv NASH: Ua rau, qhov tshwm sim, thiab txhais tau tias tiv thaiv nws. Mitochondrion 2006, 6, 1–28. [CrossRef] [PubMed]
104. Yus, Y.; Cai, J.; Nws, Z.; Li, H. Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases. Adv. Sci. 2019, 6, 1801585. [CrossRef] [PubMed]
105. Yuan, T.; Yaj, T.; Chen, H.; Fu, D.; Hu, Y.; Wang, J.; Yuan, Q. Yus, H.; Xu, W. Xie, X. Kev nkag siab tshiab rau oxidative kev nyuaj siab thiab o thaum mob ntshav qab zib mellitus-accelerated atherosclerosis. Redox Biol. 2019, 20, 247–260. [CrossRef] [PubMed]
106. Doridot, L.; Jeljeli, M.; Chaw, C.; Batteux, F. Kev cuam tshuam ntawm oxidative kev nyuaj siab nyob rau hauv lub pathogenesis ntawm kab mob sclerosis ntawm o, autoimmunity, thiab fibrosis. Redox Biol. 2019, 25, 101122. [CrossRef] [PubMed]
107. Abais, JM; Xia, M.; Li, G.; Gehr, TWB; Boini, KM; Li, P.-L. Kev koom tes ntawm endogenously tsim reactive oxygen hom rau kev ua kom cov podocyte NLRP3 inflammasomes hauv hyperhomocysteineemia. Dawb. Radic. Biol. Med. 2014, 67, 211–220. [CrossRef] [PubMed]
108. Bae, JY; Chaw ua si, HH Crystal Structure ntawm NALP3 Protein Pyrin Domain (PYD) thiab Nws Cov Kev cuam tshuam hauv Inflammasome Assembly. J. Biol. Chem. 2011, 286, 39528–39536. [CrossRef]
109. Yan, F.-J.; Zhang, X.-J.; Wang, W.-X.; Ji, Y.-X.; Wang, P.-X.; Yaj, Y.; Koob, J.; Shen, L.-J.; Zhu, X.-Y.; Huang, Z.; ua al. E3 ligase tripartite motif 8 lub hom phiaj TAK1 los txhawb cov insulin tsis kam thiab steatohepatitis. Hepatology 2017, 65, 1492–1511. [CrossRef]
110. Xiang, M.; Wang, P.-X.; Wang, AB; Zhang, X.-J.; Zhang, YJ; Zhang, P. Mei, F.-H.; Chen, M.-H.; Li, H. Targeting hepatic TRAF1-ASK1 signaling to improve inflammatory, insulin resistance, and hepatic steatosis. J. Hepatol. 2016, 64, 1365–1377. [CrossRef]
111. Wang, Y.; Wen, H.; Fu, J.; Cai, L.; Li, P.; Zhou, C.; Dong, Z.; Ma, JP; Wang, X.; Tian, H.; ua al. Hepatocyte TNF Receptor-Associated Factor 6 Aggravates Hepatic Inflammation thiab Fibrosis los ntawm Kev Txhawb Lysine 6–Txuas Polyubiquitination ntawm Apoptosis SignalRegulating Kinase 1. Hepatology 2020, 71, 93–111. [CrossRef]
112. Blaser, H.; Dostert, C.; ib. Mak, TW; Brenner, D. TNF thiab ROS Crosstalk hauv Inflammation. Trends Cell Biol. 2016, 26, 249–261. [CrossRef] [PubMed]
113. Leej Tub, Y.; Cheong, Y.-K.; Kim, N.H.; Chung, H.-T.; Kang, DG; Peb, H.-O. Mitogen-Activated Protein Kinases thiab Reactive Oxygen Hom: Yuav Ua Li Cas ROS Activate MAPK Txoj Kev? J. Signal. Kev xa tawm. 2011, 2011, 1–6. [CrossRef] [PubMed]
114. Kamata, H.; Honda, S.; Maeda, S.; Chaw, L.; Hirata, H.; Karin, M. Reactive oxygen hom txhawb nqa TNFalpha-induced tuag thiab txhawb nqa JNK ua kom los ntawm inhibiting MAP kinase phosphatase. Cell 2005, 120, 649–661. [CrossRef] [PubMed]
115. Yeej, S.; Yog, TA; Fernández-Checa, JC; Kaplowitz, N. JNK kev sib cuam tshuam nrog Sab mediates ER kev ntxhov siab vim cuam tshuam ntawm mitochondrial ua pa thiab cell tuag. Cell Tuag Dis. Xyoo 2014, 5, e989. [CrossRef] [PubMed]
116. Zhao, G.-N.; Jiang, D.-S.; Li, H. Interferon kev tswj hwm yam tseem ceeb: Ntawm kev sib tshuam ntawm kev tiv thaiv kab mob, metabolism, thiab kab mob. Biochim. Biophys. Acta Mol. Basis Dis. 2015, 1852, 365–378. [CrossRef] [PubMed]
117. Zhou, Y.; Zhang, X.-J.; Wang, P.-X.; Zhang, P. Li, H. Reprogramming Innate Immune Signaling in Cardiometabolic Disease. Ntshav siab 2017, 69, 747–760. [CrossRef] [PubMed]
118. Zhang, X.-J.; Li, H. Targeting Interferon Regulatory Factors for Cardiometabolic Diseases: Opportunities and Challenges. Curr. Lub Hom Phiaj Tshuaj 2017, 18, 1754–1778. [CrossRef]
119. Wang, XA; Zhang, R. Nws, ZG; Zhang, XF; Jiang, DS; Vang, T.; Gao, L.; Deng, W.; Zhang, SJ; Zhu, LH; ua al. Interferon regulatory factor 3 txwv tsis pub IKKbeta/NF-kappaB signaling kom txo cov hepatic steatosis thiab insulin tsis kam. Hepatology 2014, 59, 870–885. [CrossRef]
120. Yadav, UC; Ramana, KV Txoj Cai ntawm NF-kappaB-induced inflammatory signaling los ntawm lipid peroxidation-derived aldehydes. Oxidative Med. Cell. Longev. 2013, 2013, 690545. [CrossRef]
121. Morgan, MJ; Liu, ZG Crosstalk ntawm reactive oxygen hom thiab NF-kappaB signaling. Cell Res. 2011, 21, 103–115. [CrossRef]
122. Furnkranz, A.; Leitinger, N. Kev tswj cov lus teb inflammatory los ntawm oxidized phospholipids: Cov qauv kev ua haujlwm sib raug zoo. Curr. Pharm. Des. 2004, 10, 915–921. [CrossRef] [PubMed]
123. Wang, P.; ib. Zhang, X.; Li, H. Vir capsule: IRFs in hepatocytes: Pathophysiology. Hepatology 2016, 63, 1706. [CrossRef] [PubMed]
124. Luo, P.; Wang, PX; Li, ZZ; Zhang, XJ; Jiang, X.; Koob, J.; Qin, JJ; Guo, J.; Zhu, X.; Yaj, S.; ua al. Hepatic Oncostatin M Receptor beta Regulates Obesity-Induced Steatosis thiab Insulin Resistance. Am. J. Pathol. 2016, 186, 1278–1292. [CrossRef] [PubMed]
125. Ib., L.; Li, H. Innate tiv thaiv kab mob sib txuas hauv cov kab mob siab lipid metabolism. J. Mol. Med. Xyoo 2019, 97, 593–604. [CrossRef]
126. Azzimato, V.; Yog, J.; Chen, P.; Morgantini, C.; Liv, L.; Barreby, E.; Sulen, UA; Os, C.; Willerbrords, J.; ib. Xu, C.; ua al. Lub siab macrophages inhibit qhov endogenous antioxidant teb nyob rau hauv rog-associated insulin tsis kam. Sci. Txhais lus. Med. Peb Hlis 2020, 12, 9709. [CrossRef]
127. Milicevic, NP; Busch, CJ-L. Binder, CJ Malondialdehyde Epitopes raws li Lub Hom Phiaj ntawm Kev Tiv Thaiv thiab Kev cuam tshuam rau Atherosclerosis. Dev. Ua haujlwm. Myeloid Subsets 2016, 131, 1–59. [CrossRef]
128. Nobili, V.; Parola, M.; Alisi, UA; Marra, F.; Piemonte, F.; Moobello, C.; Sutti, S.; Povero, D.; Mas, V.; Novo, E.; ua al. Oxidative stress parameters nyob rau hauv cov menyuam yaus uas tsis yog-alcoholic fatty siab kab mob. Int. J. Mol. Med. 2010, 26, 471–476. [CrossRef]
129. Chou, M.-Y.; Fogelstrand, L.; ib. Hartvigsen, K.; Hansen, LF; Woelkers, D.; Shaw, PX; Choi, J.; Perkmann, T. Bäckhed, F.; Miller, YI; ua al. Oxidation-specific epitopes yog lub hom phiaj tseem ceeb ntawm cov tshuaj tiv thaiv hauv lub cev hauv cov nas thiab tib neeg. J. Clin. Tshawb xyuas. 2009, 119, 1335–1349. [CrossRef]
130. Smallwood, MJ; Nim, A.; Knight, AR; Whiteman, M.; Hais, R.; Winyard, PG Oxidative stress nyob rau hauv autoimmune rheumatic kab mob. Dawb. Radic. Biol. Med. 2018, 125, 3–14. [CrossRef]
131. Sutti, S.; Jindal, UA; Locatelli, kuv.; Vacciano, M.; Gigliotti, L.; ib. Bozzola, C.; Albano, E. Kev hloov lub cev tiv thaiv kab mob tshwm sim los ntawm oxidative kev nyuaj siab ua rau mob siab rau hauv NASH. Hepatology 2014, 59, 886–897. [CrossRef]
132. Albano, E.; Mottaran, E.; Vidal, M.; Reale, E.; Saksena, S.; Occhino, G.; Burt, AD; Hnub, CP Immune teb rau lipid peroxidation cov khoom raws li qhov kev kwv yees ntawm kev loj hlob ntawm cov kab mob uas tsis yog-alcoholic fatty siab rau siab fibrosis. Xyoo 2005, 54, 987–993. [CrossRef] [PubMed]
133. Buzzì, S.; Sutti, S.; Giudici, G.; Burlone, ME; Ramavath, NN; Toscani, UA; Bozzola, C.; Schneider, P. Morelo, E.; Parola, M.; ua al. B2-Lymphocyte cov lus teb rau oxidative stress-derived antigens pab txhawb kev hloov pauv ntawm cov kab mob uas tsis yog-coholic fatty siab (NAFLD). Dawb. Radic. Biol. Med. 2018, 124, 249–259. [CrossRef] [PubMed]
134. Baumgardner, JN; Shankar, K.; Hennings, L.; Albano, E.; Badger, TM; Ronis, MJ N-acetylcysteine ua kom txo qis kev loj hlob ntawm daim siab pathology hauv cov qauv nas ntawm cov kab mob uas tsis yog-coholic steatohepatitis. J. Nutr. Xyoo 2008, 138, 1872–1879. [CrossRef] [PubMed]
135. Rolla, S.; Alchera, E.; Imarisio, C.; Bardina, V.; Valente, G.; Cappello, P.; Moobello, C.; Follenzi, A.; Novelli, F.; Carini, R. Qhov sib npaug ntawm IL-17 thiab IL-22 tsim los ntawm daim siab-infiltrating T-helper hlwb thuam tswj NASH kev loj hlob hauv cov nas. Clin. Sci. 2015, 130, 193–203. [CrossRef] [PubMed]
136. Rau, M.; Schilling, A.-K.; Meertens, J.; Hering, ib.; Weis, J.; Jurowich, C.; Kudlich, T.; Hermanns, HM. Bantel, H.; Beyersdorf, N.; ua al. Kev loj hlob los ntawm Nonalcoholic Fatty Liver mus rau Nonalcoholic Steatohepatitis yog cim los ntawm ntau zaus ntawm Th17 Cells nyob rau hauv daim siab thiab nce Th17 / Resting Regulatory T Cell Ratio nyob rau hauv cov ntshav Peripheral thiab lub siab. J. Immunol. 2015, 196, 97–105. [CrossRef] [PubMed]
137. Inzaugarat, KUV; Solari, NEF; Billordo, LA; Abecasis, R.; Gadano, AC; Cherñavsky, AC Altered Phenotype thiab Functionality ntawm Circulating Immune Cells Characterize Adult Patients with Nonalcoholic Steatohepatitis. J. Clin. Immunol. 2011, 31, 1120–1130. [CrossRef]
138. Solari, NEF; Inzaugarat, ME; Baj, P.; De Matteo, E.; Lezama, C.; Galoppo, M.; Galoppo, C.; Cherñavsky, AC Lub luag haujlwm ntawm Innate Cells yog ua ke rau Th1-Polarized Immune Response in Pediatric Nonalcoholic Steatohepatitis. J. Clin. Immunol. 2012, 32, 611–621. [CrossRef]
139. Ma, X.; Hua, J.; Mohamood, AR; Hamad, ARA; Rau, R.; Li, Z. Kev noj zaub mov muaj roj ntau thiab tswj T hlwb ua rau muaj kev cuam tshuam rau endotoxin ua rau lub siab raug mob. Hepatology 2007, 46, 1519–1529. [CrossRef]
140. Ma, C.; Kesarwala, AH; Eggert, T.; Medina-Echeverz, J.; Kleiner, DE; Jin, P.; Stroncek, PJDF; Taub, M.; Kapoor, V.; Elgindi, M. ua al. NAFLD ua rau xaiv CD4 ntxiv rau T lymphocyte poob thiab txhawb nqa hepatocarcinogenesis. Nat. Cell Bio. 2016, 531, 253–257. [CrossRef]
141. Van Herck, MA; Weyler, J.; Kwanten, WJ; Dirinck, EL; Lub caij ntuj no, BY; Francque, SM; Vonghia, L. Lub luag haujlwm sib txawv ntawm T Cells nyob rau hauv Tsis-alcoholic Fatty Liver Disease and Obesity. Pem hauv ntej. Immunol. 2019, 10, 82. [CrossRef]
142. Laurent, S.; Carrega, P. Saverino, D.; Piccioli, P. Camoriano, M. Morabito, A.; Daws, B.; Fontana, V.; Simone, R.; Mortara, L.; ua al. CTLA-4 yog qhia los ntawm tib neeg monocyte-derived dendritic hlwb thiab tswj lawv txoj haujlwm. Hum. Immunol. Xyoo 2010, 71, 934–941. [CrossRef] [PubMed]
143. Hendrikx, T.; Watzenböck, ML; Walenbergh, SMA; Amir, S.; Gruber, S.; Kozma, MO; Grabsch, HI; Koj, GH; Pierik, MJ; Taufer, K.; ua al. Qib qis ntawm IgM cov tshuaj tiv thaiv uas paub txog oxidation-specific epitopes yog txuam nrog tib neeg cov kab mob uas tsis yog-alcoholic fatty siab kab mob. BMC Med. 2016, 14, 107. [CrossRef] [PubMed] 144. Bieghs, V.; Van Gorp, PJJ; Walenbergh, NWS; Gijbels, MJ; Verheyen, F.; Buurman, WA; Briles, DE; Hofker, MH; Binder, CJ; Shiri-Sverdlov, R. Cov tswv yim tiv thaiv kab mob tshwj xeeb tiv thaiv oxidized low-density lipoprotein: Ib txoj hauv kev tshiab los txo cov kab mob steatohepatitis hauv nas. Hepatology 2012, 56, 894–903. [CrossRef] [PubMed]
145. Kulik, L.; El-Serag, HB Epidemiology thiab Kev Tswj Xyuas Kab Mob Hepatocellular. Gastroenterology 2019, 156, 477–491.e1. [CrossRef] [PubMed]
146. Margini, C.; Dufour, J.-F. Zaj dab neeg ntawm HCC hauv NAFLD: Los ntawm kev kis mob, thoob plaws pathogenesis, kev tiv thaiv thiab kev kho mob. Lub siab Int. 2015, 36, 317–324. [CrossRef]
147. Sachdeva, M.; Chaw, YK; Arora, SK Immunology ntawm hepatocellular carcinoma. World J. Hepatol. Xyoo 2015, 7, 2080–2090. [CrossRef]
148. Fu, Y.; Chung, F.-L. Oxidative stress thiab hepatocarcinogenesis. Hepatoma Res. 2018, 4, 4. [CrossRef]
149. Yu, L.-X.; Ling, Y.; Wang, H. Lub luag hauj lwm ntawm kev tsis kho qhov mob hauv hepatocellular carcinoma kev loj hlob thiab kev loj hlob. npj Precis. Oncol. 2018, 2, 1–10. [CrossRef]
150. Medzhitov, R. Keeb kwm thiab physiological luag hauj lwm ntawm o. Xwm Txheej 2008, 454, 428–435. [CrossRef]
151. El-Serag, HB; Rudolph, KL Hepatocellular Carcinoma: Epidemiology thiab Molecular Carcinogenesis. Gastroenterology 2007, 132, 2557–2576. [CrossRef]
152. Sahasrabuddhe, VV; Gunja, MZ; Graubard, IB; Trabert, IB; Schwartz, LWM; Park, Y.; Hollenbeck, AR; Freedman, ND; McGlynn, KA Nonsteroidal Anti-inflammatory Drug Use, Chronic Liver Disease, thiab Hepatocellular Carcinoma. J. Natl. Cancer Inst. 2012, 104, 1808–1814. [CrossRef] [PubMed]
153. Yeah, CC; Lin, JT; Jeng, LB; Ho, HJ; Yang, HR; Wu, MS; Kuo, KN; Wu, CY Nonsteroidal tshuaj tiv thaiv kab mob yog cuam tshuam nrog txo kev pheej hmoo ntawm kev mob qog nqaij hlav ntxov ntxov tom qab kho daim siab phais: Kev tshawb fawb thoob tebchaws. Ann. Surg. 2015, 261, 521–526. [CrossRef] [PubMed]
154. Zappavigna, S.; Vanacore, D.; Lam, S.; Potenza, N.; Russo, UA; Ferranti, P. Dallio, M.; ib. Federico, UA; Logercio, C.; Sperlongano, P.; ua al. Silybin-Induced Apoptosis tshwm sim nyob rau hauv Parallel mus rau nce ntawm Ceramides Synthesis thiab miRNAs secretion nyob rau hauv tib neeg hepatocarcinoma Cells. Int. J. Mol. Sci. 2019, 20, 2190. [CrossRef] [PubMed]
155. Matzinger, P. Tus Qauv Kev Nyab Xeeb: Kev Ruaj Ntseg Ntawm Tus Kheej. Science 2002, 296, 301–305. [CrossRef] [PubMed]
156. Mihm, S. Danger-Associated Molecular Patterns (DAMPs): Molecular Triggers for Sterile Inflamation in the Liver. Int. J. Mol. Sci. 2018, 19, 3104. [CrossRef] [PubMed]
157. Cruz, CSD; Kang, M.-J. Mitochondrial dysfunction thiab puas-associated molecular qauv (DAMPs) nyob rau hauv cov kab mob inflammatory. Mitochondrion 2018, 41, 37–44. [CrossRef]
158. Zhang, X.; Wu, X.; Hu, Q.; Wu, J.; Wang, G.; Hong, Z.; Ren, J.-A.; Kab mob, LFTAS Mitochondrial DNA hauv daim siab mob thiab oxidative kev nyuaj siab. Lub neej Sci. 2019, 236, 116464. [CrossRef]
159. Fang, C.; Wei, X.; Wei, Y. Mitochondrial DNA nyob rau hauv cov kev cai ntawm innate tiv thaiv teb. Protein Cell 2016, 7, 11–16. [CrossRef]
160. West, AP; Shadel, GS Mitochondrial DNA nyob rau hauv lub cev tiv thaiv kab mob thiab inflammatory pathology. Nat. Rev. Immunol. 2017, 17, 363–375. [CrossRef]
161. Bao, D.; Zhao, J.; Zhou, X.; Yang, Q.; Chen, Y.; Zhu, J.; Yuan, P.; Yaj, J.; Qin, T.; Wan, S.; ua al. Mitochondrial fission-induced mtDNA kev ntxhov siab txhawb cov qog-koom nrog macrophage infiltration thiab HCC kev loj hlob. Oncogene 2019, 38, 5007–5020. [CrossRef]
162. Riley, JS; Quarato, G.; Kloix, C.; Lopez, J.; O'Prey, J.; Pearson, M.; ib. Chapman, J.; Sasaki, H.; Carlin, LWM; Passos, JF; ua al. Mitochondrial inner membrane permeabilization enables mtDNA tso tawm thaum lub sij hawm apoptosis. EMBO J. 2018, 37, 1–16. [CrossRef] [PubMed]
163. Kaczmarek, A.; Vandenabeele, P.; Krysko, DV Necroptosis: Kev Tso Tawm Ntawm Kev Puas Tsuaj-Associated Molecular Patterns thiab Nws Lub Cev Muaj Zog. Kev tiv thaiv 2013, 38, 209–223. [CrossRef] [PubMed]
164. Andersson, UA; Tracey, KJ HMGB1 Yog Lub Hom Phiaj Kho Mob rau Cov Kab Mob Sterile thiab Kab Mob. Annu. Rev. Immunol. 2011, 29, 139–162. [CrossRef] [PubMed]
165. Kazama, H.; Ricci, J.-E.; Herndon, JM; Hop, G.; Green, DR; Ferguson, TA Induction ntawm Immunological Tolerance los ntawm Apoptotic Cells Yuav Tsum Tau Caspase-Dependent Oxidation ntawm High-Mobility Group Box-1 Protein. Immunity 2008, 29, 21–32. [CrossRef]
166. Yaj, T.; Zhang, W. Vaj, L.; Xiao, C.; Gong, Y.; Huang, D.; Guo, B.; Li, Q. Xiang, Y.; Nan, Y. Co-kev coj noj coj ua ntawm cov hlwb dendritic thiab cytokine-induced killer cells zoo suppresses mob qog noj ntshav qia cell loj hlob los ntawm inhibiting txoj hauv kev hauv lub cev. BMC Cancer 2018, 18, 984. [CrossRef]
167. Dou, L.; Ib, Y.; Chen, Y.-F.; Chen, X.-P.; Thomson, AW Hepatic Dendritic Cells, Tolerogenic Liver Environment, and Liver Disease. Semin. Lub siab Dis. 2018, 38, 170–180. [CrossRef]
168. Streba, LAM; Streba, LAM; Sandulescu, DL; Xav, CC; Mitrut, P.; Cotoi, BV; Popescu, LN; Ion, DA Dendritic cells thiab hepatocellular carcinoma. Romanian J. Morphol. Embryol. Rev. Roum. Morphol. Embryol. 2014, 55, 1287–1293.
169. Chen, S.; ib. AB, SM; Tanimoto, K.; Ninomiya, T.; Yog, H.; Michitaka, K.; Horiike, N.; Onji, M. Tsis muaj CD83-cov hlwb paub tab thiab ua kom cov dendritic ntawm cov qog nqaij hlav cancer los ntawm cov neeg mob uas muaj kab mob hepatocellular carcinoma: Qhov cuam tshuam rau hepatocarcinogenesis. Cancer Lett. 2000, 148, 49–57. [CrossRef]
170. Matsui, M.; Machida, S.; Itani-Yohda, T.; Akatsuka, T. Downregulation ntawm proteasome subunits, transporter, thiab antigen kev nthuav qhia nyob rau hauv hepatocellular carcinoma, thiab lawv kho los ntawm interferon-gamma. J. Gastroenterol. Hepatol. 2002, 17, 897–907. [CrossRef]
171. Roli ´ski, J.; Hus, I. Txhaum kev tiv thaiv kab mob ntawm cov qog: Ib qho kev xav tshiab rau kev kho dendritic cell. J. Immunotoxicol. 2014, 11, 311–318. [CrossRef]
172. Ib., Y.; Fehervari, Z.; Yamaguchi, T.; Sakaguchi, S. Foxp3 ntxiv rau kev tswj hwm ntuj tsim T hlwb nyiam tsim cov khoom sib sau ua ke ntawm cov hlwb dendritic hauv vitro thiab nquag inhibit lawv cov maturation. Proc. Natl. Acad. Sci. USA 2008, 105, 10113–10118. [CrossRef] [PubMed]
173. Tang, D.; Kang, R.; Livesey, KM; Zeh, HJ; Lotze, MT High mobility pab pawg lub thawv 1 (HMGB1) activates ib qho autophagic teb rau oxidative kev nyuaj siab. Antioxidant. Redox teeb liab. 2011, 15, 2185–2195. [CrossRef] [PubMed]
174. Szlosarek, PW; Balkwill, FR Tumor necrosis factor-alpha: Lub hom phiaj muaj peev xwm rau kev kho cov qog nqaij hlav. Lancet Oncol. 2003, 4, 565–573. [CrossRef]
175. Schrader, J.; Iredale, JP Lub inflammatory microenvironment ntawm HCC-cov zajlus ua complex. J. Hepatol. Xyoo 2010, 54, 853–855. [CrossRef] [PubMed]
176. Wu, S.-D.; Ma, Y.-S.; Fang, Y.; Liu, L.-L.; Fu, D.; Shen, X. Lub luag hauj lwm ntawm microenvironment nyob rau hauv hepatocellular carcinoma txoj kev loj hlob thiab kev loj hlob. Kho Mob Cancer. Rev. 2012, 38, 218–225. [CrossRef] [PubMed]
177. Maeda, S. NF-κB, JNK, thiab TLR Signaling Pathways in Hepatocarcinogenesis. Gastroenterol. Res. Pr. 2010, 2010, 1–10. [CrossRef]
178. Kapece, D.; Fischietti, M.; Verzella, D.; Gaggiano, A.; Cicciarelli, G.; Tessitor, A.; Zazzeroni, F.; Alesse, E. Qhov Inflammatory Microenvironment nyob rau hauv Hepatocellular Carcinoma: Lub luag haujlwm tseem ceeb rau cov qog nqaij hlav sib txuas nrog Macrophages. BioMed Res. Int. 2012, 2013, 1–15. [CrossRef]
179. Komohara, Y.; Takeya, M. CAFs, and TAMs: Maestros of the qog microenvironment. J. Pathol. 2016, 241, 313–315. [CrossRef]
180. Oršoli'c, N.; Kunšti'c, M.; Koj, M.; Graˇcan, R.; Nemrava, J. Oxidative stress, polarization ntawm macrophages thiab qog angiogenesis: Kev ua tau zoo ntawm caffeic acid. Chem. Biol. Sib tham sib. 2016, 256, 111–124. [CrossRef]
181. Zhou, Y.; Choj, S.; Chen, K.; Pobezinskaya, YL; Linnoila, ib.; Liu, Z.G. ROS ua lub luag haujlwm tseem ceeb hauv kev sib txawv ntawm kev hloov pauv macrophages thiab qhov tshwm sim ntawm cov qog nqaij hlav macrophages. Cell Res. Xyoo 2013, 23, 898–914. [CrossRef]
182. Zhu, X.-D.; Zhang, J.-B.; Zhuang, P.-Y.; Zhu, H.-G.; Zhang, W. Xiong, Y.-Q.; Wu, W.-Z.; Vaj, L.; Tang, Z.-Y.; Sun, H.-C. Kev nthuav qhia siab ntawm Macrophage Colony-Stimulating Factor hauv Peritumoral Liver Tissue Associated With Poor Survival after Curative Resection of Hepatocellular Carcinoma. J. Clin. Oncol. 2008, 26, 2707–2716. [CrossRef] [PubMed]
183. Budhu, A.; Forgues, M.; Yog, Q.-H.; Jia, H.; Nws, P.; Zanetti, KA; Kammula, Tebchaws Asmeskas; Chen, Y.; Qin, L.; Tang, Z.-Y.; ua al. Kev kwv yees ntawm venous metastases, rov tshwm sim, thiab kev kuaj mob hauv hepatocellular carcinoma raws li kev tiv thaiv kab mob tshwj xeeb kos npe ntawm daim siab microenvironment. Cancer Cell 2006, 10, 99–111. [CrossRef] [PubMed]
184. Kudo, M. Immuno-Oncology hauv Hepatocellular Carcinoma: 2017 Hloov tshiab. Oncology 2017, 93, 147–159. [CrossRef] [PubMed]
185. Makarova-Rusher, OV; Medina-Echeverz, J.; Duffy, AG; Greten, TF Lub yin thiab yang ntawm kev khiav tawm thiab kev tiv thaiv kab mob hauv HCC. J. Hepatol. 2015, 62, 1420–1429. [CrossRef] [PubMed]
186. Attallah, AM; Tabl, AA; El-Sadany, M.; Ibrahim, TA; El-Dosoky, I. Dysregulation of blood lymphocyte subsets and natural killer cells in schistosomal liver cirrhosis and hepatocellular carcinoma. Z. Tuag Gesamte Exp. Med. 2003, 3, 181–185. [CrossRef] [PubMed]
187. Zhang, X. NAFLD Related-HCC: Kev Sib Raug Zoo Nrog Metabolic Disorders. Adv. Exp. Med. Biol. 2018, 1061, 55–62. [CrossRef]
188. Ormandy, LA; Hillemann, T. Wedemeyer, H.; Manns, MP; Greten, TF; Korangy, F. Ntau cov pej xeem ntawm kev tswj T Cells nyob rau hauv cov ntshav Peripheral ntawm cov neeg mob uas muaj kab mob hepatocellular. Cancer Res. 2005, 65, 2457–2464. [CrossRef]
189. Greten, TF; Ormandy, LA; Fikuart, A.; Höchst, IB; Henschen, S.; Hörning, M.; Manns, MP; Korangy, F. Tsawg-dose Cyclophosphamide Kev Kho Mob Impairs Regulatory T Cells thiab Unmasks AFP-specific CD4 ntxiv rau T-cell teb rau cov neeg mob nrog Advanced HCC. J. Immunother. 2010, 33, 211–218. [CrossRef]
190. Hoechst, B.; ib. Ormandy, LA; Ballmaier, M.; ib. Lehner, F.; Krüger, C.; Manns, MP; Greten, TF; Korangy, F. Ib Cov Neeg Tshiab ntawm Myeloid-Derived Suppressor Cells hauv Hepatocellular Carcinoma Cov Neeg Mob Induces CD4 plus CD25 plus Foxp3 plus T Cells. Gastroenterology 2008, 135, 234–243. [CrossRef]
191. Pietras, K.; Östman, A. Hallmarks of cancer: Kev cuam tshuam nrog cov qog stroma. Exp. Cell Res. 2010, 316, 1324–1331. [CrossRef]
192. Affo, S.; ib. Yog, LX; Schwabe, RF Lub luag hauj lwm ntawm Cancer-Associated Fibroblasts thiab Fibrosis nyob rau hauv daim siab Cancer. Annu. Rev. Pathol. 2017, 12, 153–186. [CrossRef] [PubMed]
193. Zhou, Y.; Yaj, B.; Du, Z.; Bai, T.; Gao, YT; Wang, YJ; Lus, C.; Wang, FM; Bai, Y. Aberrant methylation ntawm SPARC nyob rau hauv tib neeg hepatocellular carcinoma thiab nws qhov kev cuam tshuam kev kho mob. Ntiaj teb J. Gastroenterol. 2012, 18, 2043–2052. [CrossRef] [PubMed]
194. Nieto, N.; Friedman, SL; Cederbaum, AI Stimulation thiab proliferation ntawm thawj nas hepatic stellate hlwb los ntawm cytochrome P450 2E1- muab tau los ntawm reactive oxygen hom. Hepatology 2002, 35, 62–73. [CrossRef] [PubMed]
195. Barry, AE; Baldeosingh, R.; Lam, R.; Patel, K.; Zhang, K.; Dominguez, DA; Kirton, KJ; Shah, AP; Dang, H. Hepatic Stellate Cells thiab Hepatocarcinogenesis. Pem hauv ntej. Cell Dev. Biol. 2020, 8, 709. [CrossRef] [PubMed]
196. Viel, S.; ib. Marcais, A.; Guimaraes, FS-F.; Loftus, R.; Rabilloud, J.; Grau, M.; Degouve, S.; Djebali, S.; Sanlaville, UA; Charrier, E.; ua al. TGF- inhibits kev ua haujlwm thiab kev ua haujlwm ntawm NK hlwb los ntawm kev tawm tsam mTOR txoj hauv kev. Sci. Teeb liab. Peb Hlis 2016, 9, 19. [CrossRef]
197. Vermijlen, D.; Luo, D.; Froelich, CJ; Medema, JP; Kummer, JA; Willems, E.; Braet, F.; Wisse, E. Hepatic natural killer cells tsuas yog tua splenic/ntshav ntuj killer-resistant qog hlwb los ntawm txoj kev perforin/granzyme. J. Leukoc. Biol. 2002, 72, 668–676.
198. Li, T.; Yaj, Y.; Nkauj, H.; Li, H.; Koj, A.; Liu, Y.; Sau, L.; Crispe, IN; Tu, Z. Activated NK hlwb tua kab mob siab stellate hlwb ntawm p38/PI3K signaling nyob rau hauv ib tug TRAIL-kev cuam tshuam degranulation yam. J. Leukoc. Biol. Xyoo 2019, 105, 695–704. [CrossRef]
199. Singh, HD; Otano, ib.; Kev, K.; Singh, KP; Peppa, D.; Gill, Asmeskas; Böttcher, K.; Kennedy, PTF; Oben, J.; Pinzani, M.; ua al. TRAIL regulatory receptors txwv tib neeg hepatic stellate cell apoptosis. Sci. Rep. 2017, 7, 5514. [CrossRef]
200. Radaeva, S.; Vaj, L.; Radaev, S.; Jeong, W.-I.; Park, UA; Gao, B. Retinoic acid signaling sensitizes hepatic stellate hlwb rau NK cell tua los ntawm upregulation ntawm NK cell activating ligand RAE1. Am. J. Physiol. Lub siab Physiol. 2007, 293, G809–G816. [CrossRef]
201. Zhao, W.; Zhang, L. Xu, Y.; Zhang, Z.; Ren, G.; Tang, K.; Kuab, P.; Zhao, IB; Yin, Z.; Wang, X. Hepatic stellate cells txhawb cov qog nqaij hlav los ntawm kev txhim kho cov tshuaj tiv thaiv kab mob hauv lub siab orthotopic mob qog nas qauv. Lab. Tshawb xyuas. 2014, 94, 182–191. [CrossRef]
202. Ghiringhelli, F.; Menard, C.; Terme, M.; Pluas, C.; Tais, J.; Chaw, N.; Puig, PE; Novault, S.; Escudier, IB; Vivier, E.; ua al. CD4 ntxiv rau CD25 ntxiv rau kev tswj hwm T hlwb inhibit ntuj killer cell functions nyob rau hauv ib tug transforming loj hlob yam-beta-dependent yam. J. Exp. Med. 2005, 202, 1075–1085. [CrossRef] [PubMed]
203. Fu, J.; Xu, D.; Liu, Z.; Sib, M.; Zhou, P.; Fu, IB; Zhang, Z.; Yang, H.; Zhang, H. Zhou, C.; ua al. Kev tswj hwm T Cells sib txuas nrog CD8 T-Cell Impairment thiab tsis muaj sia nyob hauv cov neeg mob Hepatocellular Carcinoma. Gastroenterology 2007, 132, 2328–2339. [CrossRef] [PubMed]
204. Ju, M.-J.; Qiu, S.-J.; Gao, Q.; Fan, J.; Cai, M.-Y.; Li, Y.-W.; Tang, Z.-Y. Kev sib xyaw ua ke ntawm peritumoral mast cells thiab T-regulatory cells kwv yees qhov kev tshwm sim ntawm hepatocellular carcinoma. Cancer Sci. 2009, 100, 1267–1274. [CrossRef] [PubMed]
205. Curtsinger, JM; Schmidt, NWS; Mondino, UA; Lins, DC; Kedl, RM; Jenkins, MK. Mescher, MF Inflammatory cytokines muab lub cim thib peb rau kev ua kom tsis zoo ntawm CD4 ntxiv thiab CD8 ntxiv rau T hlwb. J. Immunol. 1999, 162, 3256–3262.
206. Lever, M.; Maini, PK; Van Der Merwe, PA; Dushek, O. Phenotypic qauv ntawm T cell activation. Nat. Rev. Immunol. 2014, 14, 619–629. [CrossRef]
207. Pardoll, DM Qhov thaiv ntawm kev tiv thaiv kab mob hauv kev kho mob qog noj ntshav. Nat. Rev. Cancer 2012, 12, 252–264. [CrossRef]
208. Jiang, Y.; Li, Y.; Zhu, B. T-cell qaug zog nyob rau hauv lub qog microenvironment. Cell Tuag Dis. Xyoo 2015, 6, e1792. [CrossRef]
209. El Dika, ib.; Khalil, DN; Abou-Alfa, GK Immune checkpoint inhibitors rau hepatocellular carcinoma. Cancer 2019, 125, 3312–3319. [CrossRef]
210. Ritz, T.; Krenkel, UA; Tacke, F. Dynamic plasticity ntawm macrophage ua haujlwm hauv daim siab mob. Cell. Immunol. 2018, 330, 175–182. [CrossRef]
211. Devisscher, L.; Verhelst, X.; Colle, ib.; Van Vlierberghe, H.; Geerts, A. Lub luag haujlwm ntawm macrophages hauv kev rog dhau-driven kab mob siab. J. Leukoc. Biol. 2016, 99, 693–698. [CrossRef]
212. Bekkering, S.; Blok, IB; Joosten, LA; Riksen, NP; van Crevel, R. Netea, MG Hauv Vitro Kev sim qauv ntawm Kev Kawm Innate Immunity hauv Tib Neeg Thawj Monocytes. Clin. Tshuaj tiv thaiv Immunol. 2016, 23, 926–933. [CrossRef] [PubMed]
213. Xu, J.; Schmidt, NWS; Sander, J.; Draffehn, A.; Kreb, W.; Quester, ib.; De Nardo, D.; Gohel, TD; Emde, M.; Schmidleithner, L. ua al. Transcriptome-based network tsom xam qhia txog tus qauv spectrum ntawm tib neeg macrophage activation. Kev tiv thaiv 2014, 40, 274–288. [CrossRef] [PubMed]
214. Moob, VP; Arts, RJ; Novakovic, IB; Matzaraki, V.; De Bree, LCJ; Koeken, VA; Moorlag, SJ; Van Puffelen, JH; Groov, L.; Van Der Heijden, CD; ua al. Lub luag haujlwm ntawm Tus Hu-zoo li receptor 10 hauv kev hloov kho ntawm kev tiv thaiv kev tiv thaiv. Immunology 2019, 159, 289–297. [CrossRef] [PubMed]
215. O'Connell, RM; Chaudhuri, AA; Rau, DS; Baltimore, D. Inositol phosphatase SHIP1 yog lub hom phiaj tseem ceeb ntawm miR-155. Proc. Natl. Acad. Sci. USA 2009, 106, 7113–7118. [CrossRef] [PubMed]
216. Quintin, J.; Saib, S.; Martens, JH; Giamarellos-Bourboulis, EJ; Ifrim, DC; Logie, C.; Jacob, L.; Jansen, T.; Kullberg, B.-J.; Wijmenga, C.; ua al. Candida albicans Infection Affords tiv thaiv kev tiv thaiv rov qab los ntawm kev ua haujlwm rov ua haujlwm ntawm Monocytes. Cell Host Microbe 2012, 12, 223–232. [CrossRef]
217. Yona, S.; Kim, KW; Hmab, Y.; Mildner, UA; Varol, D.; Breker, M.; ib. Strauss-Ayali, D.; Viukov, S.; Guilliams, M.; Misharin, A.; ua al. Txoj hmoo daim phiaj qhia txog keeb kwm thiab kev hloov pauv ntawm monocytes thiab cov ntaub so ntswg macrophages hauv homeostasis. Kev tiv thaiv 2013, 38, 79–91. [CrossRef]
218. Kleinnijenhuis, J.; Quintin, J.; Preijers, F.; Joosten, LAB; Ifrim, DC; Saib, S.; Jacob, C.; Van Loenhout, J.; De Jong, D.; Stunnenberg, HG; ua al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific tiv thaiv los ntawm reinfection ntawm epigenetic reprogramming ntawm monocytes. Proc. Natl. Acad. Sci. USA 2012, 109, 17537–17542. [CrossRef]
219. Morgillo, F.; Dallio, M.; ib. Morgillo, F.; Gravina, UA; Viscardi, G.; Logercio, C.; Ciardiello, F.; Federico, A. Carcinogenesis raws li ib tug tshwm sim ntawm ntau yam mob thiab Oxidative hits: Ib qho kev tshuaj xyuas los ntawm qog Microenvironment rau Gut Microbiota. Neoplasia 2018, 20, 721–733. [CrossRef]
220. Ganeshan, K.; Chawla, A. Metabolic Regulation of Immune Responses. Annu. Rev. Immunol. 2014, 32, 609–634. [CrossRef]
221. Sangineto, M.; Grabherr, F.; Adolph, TE; Loj, C.; Reider, S.; Jaschke, N.; maj, L.; Schwärzler, J.; Dallio, M.; ib. Moschen, AR; ua al. Dimethyl fumarate ameliorates hepatic o nyob rau hauv cawv-txog kab mob siab. Lub siab Int. Xyoo 2020, 40, 1610–1619. [CrossRef]
222. Tannahill, GM; Curtis, AM; Adamik, J.; Palsson-McDermott, EM; McGetrick, AF; Goel, G.; Frezza, C.; Bernard, NJ; Kelly, IB; Foley, NH; ua al. Succinate yog ib qho teeb meem uas ua rau IL-1 los ntawm HIF-1 . Xwm Txheej 2013, 496, 238–242. [CrossRef] [PubMed]
223. Lampropoulou, V.; Sergushichev, UA; Bambouskova, M.; Nair, S.; Vincent, EE; Loginicheva, E.; Cervantes-Barragan, L.; Ma, X.; Huang, SC-C.; Gris, T.; ua al. Itaconate Links Inhibition ntawm Succinate Dehydrogenase nrog Macrophage Metabolic Remodeling thiab kev tswj ntawm qhov mob. Cell Metab. 2016, 24, 158–166. [CrossRef] [PubMed]
224. Jha, AK; Huang, SC-C.; Sergushichev, UA; Lampropoulo, V.; Ivanova, Y.; Loginicheva, E.; Chmielewski, K.; Stewart, KM; Ashal, J.; Everts, B.; ua al. Kev koom ua ke Network ntawm Parallel Metabolic thiab Transcriptional Data Qhia Metabolic Modules uas tswj Macrophage Polarization. Kev tiv thaiv 2015, 42, 419–430. [CrossRef] [PubMed]
225. Michelucci, A.; ib. Cordes, T.; Ghelfi, J.; Pailot, UA; Reiling, N.; Goldmann, UA; Binz, T.; Wegner, UA; Talam, A.; Rausell, A.; ua al. Immune-responsive gene 1 protein txuas cov metabolism hauv kev tiv thaiv kab mob los ntawm catalyzing itaconic acid ntau lawm. Proc. Natl. Acad. Sci. USA 2013, 110, 7820–7825. [CrossRef]
226. Dominguez-Andres, J.; Novakovic, IB; Li, Y.; Scicluna, BP; Gresnigt, MS; Arts, RJ; Kev, M.; Moorlag, SJ; Groh, LA; Zuag, J.; ua al. Txoj Kev Itaconate yog ib qho kev tswj hwm hauv nruab nrab ntawm kev sib txuas ntawm Innate Immune Tolerance thiab Kev Tiv Thaiv Kev Tiv Thaiv. Cell Metab. 2019, 29, 211–220.e5. [CrossRef]
227. Xiao, W.; Vaj, L.; Xiao, R.; Wu, M.; Jinquan, T.; Nws, Y. Kev nthuav qhia profile ntawm tib neeg lub cev tiv thaiv kab mob gene 1 thiab tiam thiab cov yam ntxwv ntawm polyclonal antiserum. Mol. Cell. Biochem. 2011, 353, 177–187. [CrossRef]
228. Ganta, VC; Choi, MH; Kutateladze, A.; Fox, TE; Farber, CR; Annex, BH A MicroRNA93–Interferon Regulatory Factor-9– Immunoresponsive Gene-1–Itaconic Acid Pathway Modulates M2-Zoo li Macrophage Polarization los Revascularize Ischemic Muscle. Xyoo 2017, 135, 2403–2425. [CrossRef]
229. Bambouskova, M.; Gorvel, L.; ib. Lampropoulo, V.; Sergushichev, UA; Loginicheva, E.; Johnson, K.; Korenfeld, D.; ib. Mathyer, ME; Kim, H.; Huang, LH; ua al. Electrophilic zog ntawm itaconate thiab derivatives tswj lub IκBζ-ATF3 inflammatory axis. Xwm Txheej 2018, 556, 501–504. [CrossRef]
230. Costa, ASH; Higgins, M.; Hams, E.; Sib, J.; Runtsch, MC; Vajntxwv, MS; McGouran, JF; Fischer, R.; Kessler, IB; McGetrick, AF; ua al. Itaconate yog ib qho tshuaj tiv thaiv kab mob metabolite uas ua rau Nrf2 ntawm alkylation ntawm KEAP1. Xwm Txheej 2018, 556, 113–117.
231. Cordes, T.; Lucas, UA; Divakaruni, AS; Murphy, AN; Cabrales, P.; Metallo, CM Itaconate modulates tricarboxylic acid thiab redox metabolism los txo kev raug mob reperfusion. Mol. Metab. 2020, 32, 122–135. [CrossRef]
232. Yi, Z.; Deng, M.; Scott, MJ; Fu, G.; Loughran, PA; Li, Z.; Li, S.; Sun, P.; Yaj, C.; Li, W. ua al. IRG1/Itaconate Activates Nrf2 hauv Hepatocytes los tiv thaiv daim siab Ischemia-Reperfusion Injury. Hepatology 2020, 72, 1394–1411. [CrossRef] [PubMed]
233. Lefere, S.; Tacke, F. Macrophages nyob rau hauv rog rog thiab tsis-alcoholic fatty siab kab mob: Crosstalk nrog metabolism. JHEP Rep. 2019, 1, 30–43. [CrossRef] [PubMed]
234. Federico, A.; Dallio, M.; ib. Di Sarno, R.; Giorgio, V.; Miele, L. Gut microbiota, rog rog, thiab metabolic ntshawv siab. Minerva Gastroenterol. Paub meej. 2017, 63, 337–344. [PubMed]
